What this topic covers
This topic includes BCMA-directed cell therapy, myeloma immunotherapy, antigen escape, minimal residual disease, bispecific antibodies, safety management, and real-world outcomes.
Topic feed
Recent BCMA CAR-T Papers
Monitor B-cell maturation antigen targeted CAR-T research, especially in multiple myeloma, relapse biology, response durability, and treatment sequencing.
How to use this feed
Use the broad BCMA CAR-T query for daily monitoring, then refine with multiple myeloma, relapse, MRD, ide-cel, cilta-cel, toxicity, or bispecific antibody sequencing.
Search ideas
Useful searches to try next
Research context
How to read this topic
Why follow BCMA separately?
BCMA CAR-T has a fast-moving clinical literature with frequent updates on myeloma outcomes, resistance, toxicity, and post-relapse sequencing.
What should I watch for?
Look for durability, MRD negativity, antigen loss, immune reconstitution, neurotoxicity, and outcomes after prior bispecific or antibody exposure.